Juul Labs suffers 23% revenue drop in Q1 2022

Jul.21.2022
Juul Labs suffers 23% revenue drop in Q1 2022
Juul Labs Inc. reported a 23% revenue drop and $28 million loss in Q1 2022, amid pressure from government regulators.

According to insiders, Juul Labs Inc. suffered a loss in the first quarter of 2022, with revenue dropping by 23% compared to the previous year. The company has been trying to regain public trust during the government's crackdown on youth vaping.


According to sources, Juul presented financial data during its search for rescue financing. As of March 31st, Juul generated revenue of $259 million in the first quarter, with a pre-adjustment loss of $28 million due to interest, taxes, depreciation, and amortization. In the same period last year, the company reported revenue of $29 million.


Due to regulatory efforts to crack down on underage e-cigarette use, Juul is facing increasing sales pressure. In June, the FDA banned the placement of Juul products on shelves in the United States, citing a lack of evidence demonstrating the overall safety of the company's products and noting Juul's disproportionate role in the rise of youth e-cigarette use. Juul then won an emergency court order, temporarily halting the decision and allowing the company to continue selling its products. Juul is also facing a series of consumer lawsuits that could result in millions of dollars in damages.


The company is currently attempting to raise funds in order to gain some breathing room prior to several repayment deadlines.


According to unnamed sources, Juul currently has $323 million in cash on hand as of the first quarter, which is lower than the $428 million they had during the same period last year. Their total debt amounts to around $2.15 billion, which includes a $394 million term loan due in August 2023 and approximately $1.7 billion in "physically settled securities" notes due in 2025 that allow the company to defer interest payments.


Consideration of bankruptcy.


In addition to considering financing options, the company has been exploring various alternatives, including filing for bankruptcy. According to a Bloomberg report earlier this month, Kirkland & Ellis and Alvarez & Marsal have been providing Juul with litigation and restructuring advice.


The potential ban by the FDA is part of a long-running movement by the government to control electronic cigarette manufacturers. Flavorings such as mango and crème brûlée have helped Juul's founders become billionaires, and seem to be aimed at attracting young customers, despite the company's claims that its products offer a safer way for smokers to consume nicotine.


In 2019, Juul ceased the sale of most flavors, and the following year, the FDA prohibited the entry of sweet and fruity flavors into the market.


A spokesperson for Juul has stated that the company is exploring alternative financing options in light of ongoing FDA scrutiny and has yet to decide on any particular course of action. The statement also affirms the company's commitment to providing their product to adult consumers seeking an alternative to traditional cigarettes.


Translate into standard journalistic English:


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Indonesian drug agency chief proposes ban on e-cigarettes and e-liquid containing harmful substances
Indonesian drug agency chief proposes ban on e-cigarettes and e-liquid containing harmful substances
Indonesian drug agency chief proposes ban on e-cigarette and e-liquid in new draft law, citing dangerous substances found.
Apr.08 by 2FIRSTS.ai
Geekvape Launches New E-cigarette "KLOUD" with Unique Oil Refill and Cartridge Swapping Features
Geekvape Launches New E-cigarette "KLOUD" with Unique Oil Refill and Cartridge Swapping Features
GEEKVAPE launches new e-cigarette KLOUD, featuring hybrid design for oil filling and cartridge swapping, priced at $7.49.
Apr.01 by 2FIRSTS.ai
Special Report | Breeze and Glas Seek White House Review as FDA Advances Flavored ENDS Guidance
Special Report | Breeze and Glas Seek White House Review as FDA Advances Flavored ENDS Guidance
Breeze Smoke and Glas, Inc. have separately requested White House review under Executive Order 12866 as the FDA advances draft guidance on flavored ENDS (RIN 0910-ZC78). The guidance aims to clarify evidentiary standards under the statutory “appropriate for the protection of public health” (APPH) framework. The parallel filings highlight industry concern over regulatory predictability, particularly as Glas’s PMTA review status has recently drawn market attention.
Special Report
Mar.03
Reuters Exclusive: FDA’s Fast-Track Review of Nicotine Pouches Slows Over Youth and New-User Concerns
Reuters Exclusive: FDA’s Fast-Track Review of Nicotine Pouches Slows Over Youth and New-User Concerns
Reuters reported on April 1 that several popular nicotine pouch products still have not been cleared for sale in the United States despite a fast-track review pilot run by the U.S. Food and Drug Administration. Three sources said FDA reviewers have taken a cautious approach because of potential risks to youth and other non-tobacco users, including the possibility of driving nicotine addiction among adults who do not already smoke.
Apr.02 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Australian police seize tobacco and vape products in roadside stop: goods valued at A$784,950
Australian police seize tobacco and vape products in roadside stop: goods valued at A$784,950
Australian police say that during a roadside inspection in southern New South Wales, they seized 293,200 cigarettes, 265kg of hard-pressed tobacco leaf and 2,290 vape products from a van bearing Victorian number plates, with an estimated street value of A$784,950.
Feb.26 by 2FIRSTS.ai